TY - JOUR
T1 - A Contemporary Picture of Enterococcal Endocarditis
AU - Pericàs, Juan M.
AU - Llopis, Jaume
AU - Muñoz, Patricia
AU - Gálvez-Acebal, Juan
AU - Kestler, Martha
AU - Valerio, Maricela
AU - Hernández-Meneses, Marta
AU - Goenaga, Miguel
AU - Cobo-Belaustegui, Manuel
AU - Montejo, Miguel
AU - Ojeda-Burgos, Guillermo
AU - Sousa-Regueiro, M. Dolores
AU - de Alarcón, Arístides
AU - Ramos-Martínez, Antonio
AU - Miró, José M.
AU - Sánchez, Fernando Fernández
AU - Noureddine, Mariam
AU - Rosas, Gabriel
AU - de la Torre Lima, Javier
AU - Blanco, Roberto
AU - Boado, María Victoria
AU - Campaña Lázaro, Marta
AU - Crespo, Alejandro
AU - Goikoetxea, Josune
AU - Iruretagoyena, José Ramón
AU - Irurzun Zuazabal, Josu
AU - López-Soria, Leire
AU - Nieto, Javier
AU - Rodrigo, David
AU - Rodríguez, Regino
AU - Vitoria, Yolanda
AU - Voces, Roberto
AU - García López, M. Victoria
AU - Georgieva, Radka Ivanova
AU - Ojeda, Guillermo
AU - Rodríguez Bailón, Isabel
AU - Ruiz Morales, Josefa
AU - María Cuende, Ana
AU - Echeverría, Tomás
AU - Fuerte, Ana
AU - Gaminde, Eduardo
AU - Goenaga, Miguel Ángel
AU - Idígoras, Pedro
AU - Antonio Iribarren, José
AU - Izaguirre Yarza, Alberto
AU - Kortajarena Urkola, Xabier
AU - Reviejo, Carlos
AU - Carrasco, Rafael
AU - Climent, Vicente
AU - de Benito, Natividad
N1 - Funding Information:
This work was supported by the Ministerio de Sanidad y Consumo of Spain (FIS NCT00871104, Instituto de Salud Carlos III). Institut d'Investigacions Biom?diques Pi i Sunyer (IDIBAPS) provided a personal 80:20 research grant to Dr. Mir? from 2017 to 2019. Dr. Hernandez-Meneses held a Rio Hortega Research Grant (CM17/00062) from the Instituto de Salud Carlos III and the Ministerio de Economia y Competitividad, Madrid, from 2018 to 2020. Dr. Ojeda-Burgos has received grants for assistance to medical meetings from Pfizer, Merck Sharp & Dohme, Gilead, Janssen, and Angelini; and has been paid as a speaker in medical meetings from Janssen, Gilead, and Merck Sharp & Dohme. Dr. Mir? has received consulting honoraria and/or research grants from Angelini, Bristol-Myers Squibb, Contrafect, Genentech, Gilead Sciences, Merck Sharp and Dohme, Medtronic, Novartis, Pfizer, and ViiV. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/11
Y1 - 2020/2/11
N2 - Background: Enterococcal endocarditis (EE) is a growing entity in Western countries. However, quality data from large studies is lacking. Objectives: The purpose of this study was to describe the characteristics and analyze the prognostic factors of EE in the GAMES cohort. Methods: This was a post hoc analysis of a prospectively collected cohort of patients from 35 Spanish centers from 2008 to 2016. Characteristics and outcomes of 516 cases of EE were compared with those of 3,308 cases of nonenterococcal endocarditis (NEE). Logistic regression and Cox proportional hazards regression analysis were performed to investigate risk factors for in-hospital and 1-year mortality, as well as relapses. Results: Patients with EE were significantly older; more frequently presented chronic lung disease, chronic heart failure, prior endocarditis, and degenerative valve disease; and had higher median age-adjusted Charlson score. EE more frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001; and 35.9% vs. 28.9%; p = 0.002, respectively) but less frequently pacemakers/defibrillators (1.5% vs. 10.5%; p < 0.001), and showed higher rates of acute heart failure (45% vs. 38.3%; p = 0.005). Cardiac surgery was less frequently performed in EE (40.7% vs. 45.9%; p = 0.024). No differences in in-hospital and 1-year mortality were found, whereas relapses were significantly higher in EE (3.5% vs. 1.7%; p = 0.035). Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular complications were risk factors for mortality, whereas prior endocarditis was protective and persistent bacteremia constituted the sole risk factor for relapse. Conclusions: Besides other baseline and clinical differences, EE more frequently affects prosthetic valves and less frequently pacemakers/defibrillators. EE presents higher rates of relapse than NEE.
AB - Background: Enterococcal endocarditis (EE) is a growing entity in Western countries. However, quality data from large studies is lacking. Objectives: The purpose of this study was to describe the characteristics and analyze the prognostic factors of EE in the GAMES cohort. Methods: This was a post hoc analysis of a prospectively collected cohort of patients from 35 Spanish centers from 2008 to 2016. Characteristics and outcomes of 516 cases of EE were compared with those of 3,308 cases of nonenterococcal endocarditis (NEE). Logistic regression and Cox proportional hazards regression analysis were performed to investigate risk factors for in-hospital and 1-year mortality, as well as relapses. Results: Patients with EE were significantly older; more frequently presented chronic lung disease, chronic heart failure, prior endocarditis, and degenerative valve disease; and had higher median age-adjusted Charlson score. EE more frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001; and 35.9% vs. 28.9%; p = 0.002, respectively) but less frequently pacemakers/defibrillators (1.5% vs. 10.5%; p < 0.001), and showed higher rates of acute heart failure (45% vs. 38.3%; p = 0.005). Cardiac surgery was less frequently performed in EE (40.7% vs. 45.9%; p = 0.024). No differences in in-hospital and 1-year mortality were found, whereas relapses were significantly higher in EE (3.5% vs. 1.7%; p = 0.035). Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular complications were risk factors for mortality, whereas prior endocarditis was protective and persistent bacteremia constituted the sole risk factor for relapse. Conclusions: Besides other baseline and clinical differences, EE more frequently affects prosthetic valves and less frequently pacemakers/defibrillators. EE presents higher rates of relapse than NEE.
KW - enterococci
KW - epidemiology
KW - heart failure
KW - infective endocarditis
KW - prosthetic valves
KW - relapses
UR - http://www.scopus.com/inward/record.url?scp=85078227981&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.11.047
DO - 10.1016/j.jacc.2019.11.047
M3 - Artículo
C2 - 32029130
AN - SCOPUS:85078227981
SN - 0735-1097
VL - 75
SP - 482
EP - 494
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -